RxDoctor Payments Data

Daniel Kurz, DO

Internal Medicine · Wynnewood, PANPI 1922530328

Payments from drug & device makers

$339in general payments, 2019–2025

Across 16 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$116
  • Laborie Medical Technologies Corp.$39
  • Pfizer$37
  • Almatica Pharma LLC$32
  • AstraZeneca$31
  • E.r. Squibb & Sons, L.L.C.$30
  • plus $55 from 3 others

What the payments were for

  • Food & beverage$339100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$339 in reported general payments places this provider in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$78,141
Medicare patients
226
Services billed
815

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$45,215
JardianceEmpagliflozin29$40,353
MounjaroTirzepatide38$38,363
TrulicityDulaglutide26$26,588
EliquisApixaban18$24,504
XareltoRivaroxaban15$20,693
JanuviaSitagliptin Phosphate13$11,205
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,091
Atorvastatin Calcium251$3,048
Valsartan71$2,949
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,603
Novolog FlexpenInsulin Aspart12$2,575
Rosuvastatin Calcium145$2,216
Nifedipine ErNifedipine41$1,683
Albuterol Sulfate HfaAlbuterol Sulfate46$1,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$116$45,21531 claims
PfizerEliquis$37$24,50418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →